Want to see INBX full AI Analyst Report?
Pembrolizumab, Inbrx-106
Head And Neck Squamous Cell Carcinoma (Hnscc)
Phase II/III
Recruiting
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Feb 22, 2024
―
Inbrx-109
Conventional Chondrosarcoma
Phase II
Recruiting
Study of INBRX-109 in Conventional Chondrosarcoma
Jun 14, 2021
―
Inbrx-106 - Hexavalent Ox40 Agonist Antibody, Pembrolizumab 200 Mg, Pembrolizumab 400 Mg, Carboplatin Auc-5, Carboplatin Auc-6, Pemetrexed 500 Mg/M2, Cisplatin 75Mg/M2, Paclitaxel 200Mg/M2, Nab Paclitaxel 100Mg/M2
Melanoma, Urothelial Carcinoma, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor, Gastric Cancer, Head And Neck Cancer
Phase I/II
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Dec 11, 2019
―
Irinotecan, Pemetrexed, Carboplatin, Cisplatin, Temozolomide, 5-Fluorouracil, Inbrx-109
Colorectal Adenocarcinoma, Ewing Sarcoma
Phase I
Recruiting
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Oct 11, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Inhibrx Biosciences Inc (INBX) have in its pipeline
INBX is currently developing the following drugs: Pembrolizumab, Inbrx-106, Inbrx-109, Inbrx-106 - Hexavalent Ox40 Agonist Antibody, Pembrolizumab 200 Mg, Pembrolizumab 400 Mg, Carboplatin Auc-5, Carboplatin Auc-6, Pemetrexed 500 Mg/M2, Cisplatin 75Mg/M2, Paclitaxel 200Mg/M2, Nab Paclitaxel 100Mg/M2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.